Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...
FDA approves GSK's Exdensur for severe eosinophilic asthma, backed by Phase 3 data showing up to 58% fewer asthma attacks ...
The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.
A 6-year-old boy died after he suffered a 'severe asthma attack' during a shopping trip with his mom. Magnus Landon Kayde ...
The Well News on MSN
FDA approves add-on treatment for severe asthma
WASHINGTON - The Food and Drug Administration has approved Exdensur as an add-on maintenance treatment for patients aged 12 ...
The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...
An asthma attack is a sudden worsening of asthma symptoms caused by inflammation and a narrowing of the airways. This can make breathing difficult and, in severe cases, be life-threatening. Asthma ...
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur ...
Driving away from the pharmacy to pick up a standard refill of her husband’s asthma medication, Shanon Schmidtknecht’s head was spinning. Shanon and her husband, Bill, were reeling from the death of ...
Children’s Health Ireland (CHI) has issued a ‘sincere apology’ for shortcomings in the care of a Dublin teenager who died following a severe asthma attack while waiting over four years to see a ...
Blood eosinophil count and fractional exhaled nitric oxide (FeNO) play an important role in selecting biological therapies for severe asthma. This analysis of patient-level data pooled across 22 ...
Exdensur is the first and only ultra-long-acting biologic for patients with severe asthma with an eosinophilic phenotype.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback